These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

218 related items for PubMed ID: 14669170

  • 1. Effect of pramlintide on A1C and body weight in insulin-treated African Americans and Hispanics with type 2 diabetes: a pooled post hoc analysis.
    Maggs D, Shen L, Strobel S, Brown D, Kolterman O, Weyer C.
    Metabolism; 2003 Dec; 52(12):1638-42. PubMed ID: 14669170
    [Abstract] [Full Text] [Related]

  • 2. Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes.
    Ratner RE, Want LL, Fineman MS, Velte MJ, Ruggles JA, Gottlieb A, Weyer C, Kolterman OG.
    Diabetes Technol Ther; 2002 Dec; 4(1):51-61. PubMed ID: 12017421
    [Abstract] [Full Text] [Related]

  • 3. Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients.
    Hollander P, Maggs DG, Ruggles JA, Fineman M, Shen L, Kolterman OG, Weyer C.
    Obes Res; 2004 Apr; 12(4):661-8. PubMed ID: 15090634
    [Abstract] [Full Text] [Related]

  • 4. Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial.
    Ratner RE, Dickey R, Fineman M, Maggs DG, Shen L, Strobel SA, Weyer C, Kolterman OG.
    Diabet Med; 2004 Nov; 21(11):1204-12. PubMed ID: 15498087
    [Abstract] [Full Text] [Related]

  • 5. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial.
    Hollander PA, Levy P, Fineman MS, Maggs DG, Shen LZ, Strobel SA, Weyer C, Kolterman OG.
    Diabetes Care; 2003 Mar; 26(3):784-90. PubMed ID: 12610038
    [Abstract] [Full Text] [Related]

  • 6. A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes.
    Whitehouse F, Kruger DF, Fineman M, Shen L, Ruggles JA, Maggs DG, Weyer C, Kolterman OG.
    Diabetes Care; 2002 Apr; 25(4):724-30. PubMed ID: 11919132
    [Abstract] [Full Text] [Related]

  • 7. Addition of pramlintide to insulin therapy lowers HbA1c in conjunction with weight loss in patients with type 2 diabetes approaching glycaemic targets.
    Hollander P, Ratner R, Fineman M, Strobel S, Shen L, Maggs D, Kolterman O, Weyer C.
    Diabetes Obes Metab; 2003 Nov; 5(6):408-14. PubMed ID: 14617226
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Pramlintide improved glycemic control and reduced weight in patients with type 2 diabetes using basal insulin.
    Riddle M, Frias J, Zhang B, Maier H, Brown C, Lutz K, Kolterman O.
    Diabetes Care; 2007 Nov; 30(11):2794-9. PubMed ID: 17698615
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Effect of pramlintide as an adjunct to basal insulin on markers of cardiovascular risk in patients with type 2 diabetes.
    Wysham C, Lush C, Zhang B, Maier H, Wilhelm K.
    Curr Med Res Opin; 2008 Jan; 24(1):79-85. PubMed ID: 18031595
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Impact of Disease Duration on the Effects of Pramlintide in Type 1 Diabetes: A Post Hoc Analysis of Three Clinical Trials.
    Herrmann K, Brunell SC, Li Y, Zhou M, Maggs DG.
    Adv Ther; 2016 May; 33(5):848-61. PubMed ID: 27071768
    [Abstract] [Full Text] [Related]

  • 16. Pramlintide as an adjunct to insulin in patients with type 2 diabetes in a clinical practice setting reduced A1C, postprandial glucose excursions, and weight.
    Karl D, Philis-Tsimikas A, Darsow T, Lorenzi G, Kellmeyer T, Lutz K, Wang Y, Frias JP.
    Diabetes Technol Ther; 2007 Apr; 9(2):191-9. PubMed ID: 17425446
    [Abstract] [Full Text] [Related]

  • 17. Pramlintide, a synthetic analog of human amylin, improves the metabolic profile of patients with type 2 diabetes using insulin. The Pramlintide in Type 2 Diabetes Group.
    Thompson RG, Pearson L, Schoenfeld SL, Kolterman OG.
    Diabetes Care; 1998 Jun; 21(6):987-93. PubMed ID: 9614619
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Diabetes distress and its association with clinical outcomes in patients with type 2 diabetes treated with pramlintide as an adjunct to insulin therapy.
    Peyrot M, Rubin RR, Polonsky WH.
    Diabetes Technol Ther; 2008 Dec; 10(6):461-6. PubMed ID: 19049375
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and harms of the hypoglycemic agent pramlintide in diabetes mellitus.
    Lee NJ, Norris SL, Thakurta S.
    Ann Fam Med; 2010 Dec; 8(6):542-9. PubMed ID: 21060125
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.